The 7 major galactosemia markets reached a value of US$ 341.0 Million in 2023. Looking forward, the publisher expects the 7MM to reach US$ 501.7 Million by 2034, exhibiting a growth rate (CAGR) of 4.38% during 2023-2034.
The galactosemia market has been comprehensively analyzed in this report titled "Galactosemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Galactosemia refers to a rare genetic disorder that affects the body's ability to process galactose, a sugar found in milk and other dairy products. Some of the common symptoms of the ailment are failure to thrive, poor weight gain, jaundice, liver damage, vomiting, diarrhea, feeding difficulties in infants, etc. Cataracts, which can impair vision, are a characteristic feature of galactosemia and can occur in infancy or childhood. Various other potential indications include developmental delays, intellectual disabilities, speech difficulties, tremors, hypoglycemia, ovarian failure in females, etc. The condition is diagnosed through a combination of clinical evaluation, biochemical testing, and genetic analysis. Newborn screening programs play a crucial role in identifying infants with galactosemia shortly after birth by analyzing elevated levels of galactose or its metabolites in the blood. Confirmatory diagnostic testing involves further analysis of enzyme activity, such as measuring GALT or other relevant enzyme levels in red blood cells. Genetic testing can also be performed to identify specific gene mutations associated with galactosemia. Additionally, clinical evaluation and assessment of symptoms, along with family history, contribute to the diagnosis.
The increasing cases of inherited disorders, which lead to reduced or absent enzyme activity on account of gene variations, are primarily driving the galactosemia market. Besides this, the widespread adoption of prebiotics like galacto-oligosaccharides and probiotics for improving digestion and overall gastrointestinal health in patients is acting as another significant growth-inducing factor. Furthermore, the escalating usage of pharmacological chaperones, since they offer a convenient and non-invasive treatment option for individuals with galactosemia, is also bolstering the market growth. These agents bind to the defective enzyme, which is responsible for galactose metabolism, and help in preventing its degradation by increasing the stability. Additionally, several key players are making extensive investments in R&D activities to introduce compounds that inhibit galactose production and promote the removal of toxic metabolites. This, in turn, is further creating a positive outlook for the market. Moreover, the emerging popularity of mRNA therapies that boost the production of deficient enzymes and potentially restore the body's ability to metabolize galactose is expected to drive the galactosemia market in the coming years.
This report provides an exhaustive analysis of the galactosemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for galactosemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the galactosemia market in any manner.
The galactosemia market has been comprehensively analyzed in this report titled "Galactosemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Galactosemia refers to a rare genetic disorder that affects the body's ability to process galactose, a sugar found in milk and other dairy products. Some of the common symptoms of the ailment are failure to thrive, poor weight gain, jaundice, liver damage, vomiting, diarrhea, feeding difficulties in infants, etc. Cataracts, which can impair vision, are a characteristic feature of galactosemia and can occur in infancy or childhood. Various other potential indications include developmental delays, intellectual disabilities, speech difficulties, tremors, hypoglycemia, ovarian failure in females, etc. The condition is diagnosed through a combination of clinical evaluation, biochemical testing, and genetic analysis. Newborn screening programs play a crucial role in identifying infants with galactosemia shortly after birth by analyzing elevated levels of galactose or its metabolites in the blood. Confirmatory diagnostic testing involves further analysis of enzyme activity, such as measuring GALT or other relevant enzyme levels in red blood cells. Genetic testing can also be performed to identify specific gene mutations associated with galactosemia. Additionally, clinical evaluation and assessment of symptoms, along with family history, contribute to the diagnosis.
The increasing cases of inherited disorders, which lead to reduced or absent enzyme activity on account of gene variations, are primarily driving the galactosemia market. Besides this, the widespread adoption of prebiotics like galacto-oligosaccharides and probiotics for improving digestion and overall gastrointestinal health in patients is acting as another significant growth-inducing factor. Furthermore, the escalating usage of pharmacological chaperones, since they offer a convenient and non-invasive treatment option for individuals with galactosemia, is also bolstering the market growth. These agents bind to the defective enzyme, which is responsible for galactose metabolism, and help in preventing its degradation by increasing the stability. Additionally, several key players are making extensive investments in R&D activities to introduce compounds that inhibit galactose production and promote the removal of toxic metabolites. This, in turn, is further creating a positive outlook for the market. Moreover, the emerging popularity of mRNA therapies that boost the production of deficient enzymes and potentially restore the body's ability to metabolize galactose is expected to drive the galactosemia market in the coming years.
This report provides an exhaustive analysis of the galactosemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for galactosemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the galactosemia market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the galactosemia market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the galactosemia market
Competitive Landscape:
This report also provides a detailed analysis of the current galactosemia marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the galactosemia market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the galactosemia market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the galactosemia market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of galactosemia across the seven major markets?
- What is the number of prevalent cases (2018-2034) of galactosemia by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of galactosemia by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with galactosemia across the seven major markets?
- What is the size of the galactosemia patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of galactosemia?
- What will be the growth rate of patients across the seven major markets?
Galactosemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for galactosemia drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the galactosemia market?
- What are the key regulatory events related to the galactosemia market?
- What is the structure of clinical trial landscape by status related to the galactosemia market?
- What is the structure of clinical trial landscape by phase related to the galactosemia market?
- What is the structure of clinical trial landscape by route of administration related to the galactosemia market?
Table of Contents
?1 Preface3 Executive Summary6 Patient Journey9 Galactosemia - Unmet Needs10 Galactosemia - Key Endpoints of Treatment13. Galactosemia - Attribute Analysis of Key Marketed and Pipeline Drugs16 Galactosemia - Recent Events and Inputs From Key Opinion Leaders18 Galactosemia Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Galactosemia - Introduction
5 Galactosemia - Disease Overview
7 Galactosemia - Epidemiology and Patient Population
8 Galactosemia - Treatment Algorithm, Guidelines, and Medical Practices
11 Galactosemia - Marketed Products
12 Galactosemia - Pipeline Drugs
14. Galactosemia - Clinical Trial Landscape
15 Galactosemia - Market Scenario
17 Galactosemia Market - SWOT Analysis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 137 |
| Published | May 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 341 Million |
| Forecasted Market Value ( USD | $ 501.7 Million |
| Compound Annual Growth Rate | 3.6% |
| Regions Covered | Global |
